Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation

C. O. Freytes, D. H. Vesole, J. LeRademacher, X. Zhong, R. P. Gale, R. A. Kyle, D. E. Reece, J. Gibson, H. C. Schouten, P. L. McCarthy, S. Lonial, A. Y. Krishnan, A. Dispenzieri, P. N. Hari*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

41 Citations (Web of Science)


There is no standard therapy for multiple myeloma relapsing after an autotransplant. We compared the outcomes of a second autotransplant (N=137) with those of an allotransplant (N=152) after non-myeloablative or reduced-intensity conditioning (NST/RIC) in 289 subjects reported to the CIBMTR from 1995 to 2008. NST/RIC recipients were younger (median age 53 vs 56 years; P
Original languageEnglish
Pages (from-to)416-421
JournalBone Marrow Transplantation
Issue number3
Publication statusPublished - Mar 2014


  • multiple myeloma
  • allogeneic
  • salvage transplant

Cite this